Skip to content

ASND changes

Pick any two versions below to diff them.

View the full Nov 14, 2026 version
Price
$252.73
Discount category
Below intrinsic value
Intrinsic value source
AI estimate
Next earnings
Feb 12, 2027
Next earnings is estimate
Yes
Company name
added: Ascendis Pharma
Sector
added: Biotech for rare endocrine diseases
About
added: Ascendis Pharma A/S (ASND) is a Danish biopharmaceutical company based in Hellerup, near Copenhagen. Its TransCon technology releases a drug slowly in the body, so patients need fewer doses. It sells three products for rare endocrine diseases: YORVIPATH for hypoparathyroidism in adults, SKYTROFA, a once-weekly growth hormone, and YUVIWEL, a once-weekly treatment for children with achondroplasia that the FDA approved in February 2026. Product revenue was €366 million in Q3 2026. Since April 20, 2026, the ordinary shares trade directly on Nasdaq in US dollars, in place of the ADSs. Ascendis reports in euros under IFRS and files 20-F and 6-K reports with the SEC.
Thesis
added: The price of Ascendis depends on how long the fast growth of YORVIPATH continues and on how much of the achondroplasia market YUVIWEL can take. Product revenue grew 89% in Q3 2026 to €366 million and the operating margin was 34%, so Ascendis now makes a profit and buys back shares. Investors cannot yet see how fast US demand for YORVIPATH will grow, because new patient demand there was steady, not rising. Ascendis also pays BioMarin royalties of 18% to 20% on YUVIWEL sales until May 2030. The AI estimate rests on three conditions. YORVIPATH must keep its growth with launches in more countries. TransCon CNP must get EU approval in Q4 2026 and a good launch in Germany in Q1 2027. Cash flow from operating activities must reach at least €600 million in 2026, as the company expects. The Q4 2026 report, expected in February 2027, and the pivotal data in infants in Q3 2027 are the next tests. If YORVIPATH growth slows, the value can fall a lot.
Valuation
added: The intrinsic value for Ascendis Pharma is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the reports of Ascendis Pharma in euros that it files with the SEC on Forms 6-K and 20-F. The values are in US dollars per ordinary share, because the ordinary shares trade on Nasdaq in US dollars since April 20, 2026. The method is a multiple of the 2028 operating profit after tax, discounted one year at 9%, plus net cash, divided by the diluted shares and converted to US dollars. The Q3 2026 release (6-K, November 12, 2026) gives product revenue of €366 million for Q3, with YORVIPATH at €291 million, SKYTROFA at €59 million and YUVIWEL at €16 million. It gives an operating profit of €125 million, or €156 million on a non-IFRS basis, a margin of 42%. It expects 2026 cash flow from operating activities of at least €600 million. The interim report for the quarter (6-K, November 12, 2026) gives cash of €964.4 million, royalty funding liabilities of €302.1 million and lease liabilities of €145.7 million at September 30, 2026. It gives 66,400,738 shares, of which 805,528 were treasury shares, a dilution effect of 2,965,732 warrants and RSUs in Q3, and 1,204,695 shares that Ascendis bought back after September 30 for about $273.4 million. So the estimate uses 67,356,247 diluted shares and net cash of €269 million after the buybacks, royalty funding and leases. It does not add the deferred tax assets of €652 million, and it assumes that the multiples allow for them. The estimate assumes the ECB reference rate of 1.1052 US dollars per euro of November 13, 2026. The 2028 revenue, the margins, a tax rate of 22% and the multiples are assumptions. The margins include the royalty to BioMarin of 20% in the US and 18% in some other countries on YUVIWEL until May 2030 (6-K, August 31, 2026). The low case assumes 2028 revenue of €2.0 billion, because YORVIPATH growth slows, an operating margin of 38% and 18 times. It gives $165.04 per share. The base case assumes €2.6 billion, a margin of 45% and 22 times. It gives $306.66 per share. The high case assumes €3.1 billion, with a strong YUVIWEL launch, a margin of 50% and 25 times. It gives $459.41 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $309.44 per share. Patents on the TransCon products, US orphan drug exclusivity for YUVIWEL and a positive EU opinion for 10 years of orphan market exclusivity protect the products for a number of years, but Ascendis depends on three products, and other companies develop treatments for the same diseases. As of Nov 14, 2026.
Risks
added: YORVIPATH gave €740 million of the €921 million of product revenue in the first nine months of 2026. Slower patient growth, lower prices or a new competitor can reduce revenue and value a lot. The FDA approved YUVIWEL under accelerated approval, so continued approval can depend on more data. The royalties of 18% to 20% to BioMarin until May 2030 reduce its margin, and new or better treatments from other companies can reduce demand. Ascendis depends on third-party manufacturers, distributors and service providers. A supply or quality problem can stop sales of a product. Pricing and reimbursement decisions by payers and health technology assessments in the US and Europe can limit the price and the number of patients. Ascendis reports in euros, but most sales are in US dollars and the shares trade in US dollars. Currency changes can change the reported results.
Balance sheet
added: Cash: €964M Debt: €302M Net cash: €662M At September 30, 2026, Ascendis had cash and cash equivalents of €964 million, up from €616 million at December 31, 2025. All 2.25% convertible notes due 2028 converted into 3,635,813 ordinary shares in May 2026, so there is no convertible debt. Borrowings were royalty funding liabilities of €302 million, which Ascendis repays from future sales, and lease liabilities of €146 million. Total equity was €1,500 million, up from a deficit of €163 million, mainly because of the profit, which includes the recognition of deferred tax assets, and the conversion of the notes. After September 30, 2026, Ascendis used about $273 million to buy back 1,204,695 shares. As of Sep 30, 2026.
Checkpoints
added: Q4 2026 (estimate): EU decision on TransCon CNP. Pending. Watch: The European Commission approves TransCon CNP for children with achondroplasia in Q4 2026, and this passes; a delay past Q1 2027 or a refusal fails. Feb 12, 2027 (estimate): Q4 2026 results. Pending. Watch: Cash flow from operating activities is at least €600 million for 2026 and product revenue grows again from Q3 2026, and this passes; a miss of either fails. Q3 2027 (estimate): Pivotal data of TransCon CNP in infants. Pending. Watch: The pivotal reACHin data in infants younger than two years show a clear growth benefit with good safety, and this passes; weak data or a safety problem fail.
Recent events
added: Nov 12, 2026: Ascendis reported Q3 2026 results. Product revenue grew 89% to €366 million: YORVIPATH €291 million, SKYTROFA €59 million and YUVIWEL €16 million. Operating profit was €125 million and net profit was €74 million, or €1.08 per diluted share. Ascendis expects 2026 cash flow from operating activities of at least €600 million. Through November 11, it bought back 1,998,999 shares in 2026 for $459 million. Oct 16, 2026: The CHMP of the European Medicines Agency recommended EU approval of TransCon CNP for children with achondroplasia from two years of age. Ascendis expects the European Commission decision in Q4 2026. Sep 14, 2026: The board approved a share repurchase program of up to $400 million. Ascendis also got back the rights to TransCon products in metabolic and cardiovascular diseases, including obesity, after the end of its collaboration with Novo Nordisk. Aug 31, 2026: Ascendis agreed a binding term sheet with BioMarin to settle all litigation about YUVIWEL. BioMarin gives a worldwide license, and Ascendis pays royalties on net sales of 20% in the US and 18% in the EU, South Korea and Brazil until May 20, 2030. Jun 17, 2026: Ascendis sold the rare pediatric disease priority review voucher that it got with the approval of YUVIWEL for $187.5 million in cash. May 6, 2026: All holders of the 2.25% convertible notes due 2028 converted their notes, and Ascendis delivered 3,635,813 ordinary shares. Apr 20, 2026: The ordinary shares started to trade directly on Nasdaq under the ticker ASND, and all ADSs were exchanged for ordinary shares. Feb 27, 2026: The FDA approved YUVIWEL under its Accelerated Approval Program to increase linear growth in children with achondroplasia from two years of age. It became available in the US on April 6, 2026, with orphan drug exclusivity.